Cantor Fitzgerald Maintains Overweight on Theseus Pharmaceuticals, Lowers Price Target to $7
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Alethia Young has maintained an Overweight rating on Theseus Pharmaceuticals (NASDAQ:THRX) but lowered the price target from $23 to $7.
July 14, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Theseus Pharmaceuticals but lowered the price target from $23 to $7.
The lowering of the price target by Cantor Fitzgerald from $23 to $7 indicates a potential decrease in the short-term value of Theseus Pharmaceuticals' stock. This could lead to a negative impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100